MATTHEW CLEMENTE

Vice President, Device Development, Device R&D, Novo Nordisk

Matthew James Clemente currently serves as the Vice President of Device Development at Novo Nordisk. He is responsible for the leadership of the engineering and portfolio management of Novo’s drug delivery and connected devices.

Matthew previously served as the Senior Director and Chief Technology Officer at Eli Lilly & Company, where he developed a portfolio of electromechanical delivery devices, applications and algorithms that served as the foundation of Eli Lilly’s connected diabetes ecosystem. Prior to that, he was the Director of Advanced Drug Delivery Systems at Unilife Corporation where he built and managed an integrated engineering and science organization focused on mechanical, electromechanical, digital and container closure systems for prefilled, preassembled, wearable drug delivery applications. Prior to Unilife, Matthew held a variety of roles of increasing responsibility at multiple Johnson & Johnson companies, where he primarily served in the new product development of insulin pumps at Animas Corporation for J&J’s Diabetes Care Franchise.

By way of education, Matthew obtained a Bachelor of Science in Biomedical Engineering from the University of Miami and an MBA in Finance from Villanova University.